Nuformix plc, a pharma company specializing in fibrosis and oncology, is raising funds through a share placement for drug development and corporate needs.
Nuformix plc, a pharmaceutical company focusing on fibrosis and oncology through drug repurposing, presents its audited results and strategic priorities for 2024.
Nuformix plc targets fibrosis and oncology needs with NXP002. Company applies for Orphan Drug Designation in Europe for novel IPF treatment.
Nuformix plc targets medical needs in fibrosis and oncology. The company has submitted a draft application for an Orphan Drug Designation with the EMA.
Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding caught up with DirectorsTalk for an exclusive interview to discuss recent patents for NXP002 & NXP004, highlights from interim results, and what’s
Nuformix Plc (LON:NFX), a pharmaceutical development company focused on drug repurposing for fibrosis and oncology, recently provided a patent update for its NXP002 and NXP004 programs, as well as its interim
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 31 March 2024. Operational highlights
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the eighteen months ended 30 September 2023 following the
Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated
Nuformix plc (LON: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that it has been issued with an Official Decision to Grant
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
